An evaluation of zonisamide, including its long-term efficacy, for the treatment of focal epilepsy

References

• Hirtz D, Thurman DJ, Gwinn-Hardy K, et al. How common are the “common” neurologic disorders? Neurology. 2007 Jan 30;68(5):326–337.
   PubMed Web of Science ®Google Scholar
• Ngugi AK, Bottomley C, Kleinschmidt I, et al. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia. 2010 May;51(5):883–890.
   PubMed Web of Science ®Google Scholar
• Fisher RS. The new classification of seizures by the international league against epilepsy 2017. Curr Neurol Neurosci Rep. 2017 Jun;17(6):48.
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Bamagous G, Kwan P. Improved outcomes in newly diagnosed epilepsy. Epilepsia. 2009;50(Suppl. 11):411–412.
   Google Scholar
• Duncan JS. The promise of new antiepileptic drugs. Br J Clin Pharmacol. 2002 Feb;53(2):123–131.
   PubMed Web of Science ®Google Scholar
• Kalilani L, Sun X, Pelgrims B, et al. The epidemiology of drug-resistant epilepsy: A systematic review and meta-analysis. Epilepsia. 2018 Dec;59(12):2179–2193.
   PubMed Web of Science ®Google Scholar
• Rosati A, De Masi S, Guerrini R. Antiepileptic drug treatment in children with epilepsy. CNS Drugs. 2015;29(10):847–863.
   PubMed Web of Science ®Google Scholar
• Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. Neurology. 2017 Jan 17;88(3):296–303.
   PubMed Web of Science ®Google Scholar
• Specht U, Coban I, Bien CG, et al. Risk factors for early disability pension in patients with epilepsy and vocational difficulties - Data from a specialized rehabilitation unit. Epilepsy Behav. 2015 Oct;51:243–248.
   PubMed Web of Science ®Google Scholar
• Cardarelli WJ, Smith BJ. The burden of epilepsy to patients and payers. Am J Manag Care. 2010 Dec;16(12 Suppl):S331–S336.
   PubMed Web of Science ®Google Scholar
• Laxer KD, Trinka E, Hirsch LJ, et al. The consequences of refractory epilepsy and its treatment. Epilepsy Behav. 2014;37:59–70.
   PubMed Web of Science ®Google Scholar
• Makinen J, Peltola J, Raitanen J, et al. Comparative effectiveness of eight antiepileptic drugs in adults with focal refractory epilepsy: the influence of age, gender, and the sequence in which drugs were introduced onto the market. J Neurol. 2017 Jul;264(7):1345–1353.
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Koepp MJ, et al. Progress report on new antiepileptic drugs: A summary of the fourteenth Eilat conference on new antiepileptic drugs and devices (EILAT XIV). I. Drugs in preclinical and early clinical development. Epilepsia. 2018 Oct;59(10):1811–1841.
   PubMed Web of Science ®Google Scholar
• Golyala A, Kwan P. Drug development for refractory epilepsy: the past 25 years and beyond. Seizure. 2017 Jan;44:147–156.
   PubMed Web of Science ®Google Scholar
• Shah J, Shellenberger K, Canafax DM. Zonisamide - chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. 5 ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 873–879.
   Google Scholar
• Masuda Y, Ishizaki M, Zonisamide: SM. Pharmacology and Clinical Efficacy in Epilepsy. CNS Drug Rev. 1998 Dec;4(4):341–360.
   PubMedGoogle Scholar
• Ueda Y, Doi T, Tokumaru J, et al. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res. 2003 Aug 19;116(1–2):1–6.
   PubMedGoogle Scholar
• Uemura MT, Asano T, Hikawa R, et al. Zonisamide inhibits monoamine oxidase and enhances motor performance and social activity. Neurosci Res. 2017 Nov;124:25–32.
   PubMed Web of Science ®Google Scholar
• Kumar B, Medhi B, Modi M, et al. A mechanistic approach to explore the neuroprotective potential of zonisamide in seizures. Inflammopharmacology. 2018 Aug;26(4):1125–1131.
   PubMed Web of Science ®Google Scholar
• Seino M. Review of zonisamide development in Japan. Seizure. 2004 Dec;13(Suppl 1):S2–S4.
   PubMed Web of Science ®Google Scholar
• Grover ND, Limaye RP, Gokhale DV, et al. Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson’s disease. Indian J Pharmacol. 2013 Nov-Dec;45(6):547–555.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Yanagihashi M, Miura K, et al. Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: A retrospective, observational cohort study. J Neurol Sci. 2018 Aug;15(391):5–9.
   Web of Science ®Google Scholar
• Bagnato F, Good J. The use of antiepileptics in migraine prophylaxis. Headache. 2016 Mar;56(3):603–615.
   PubMed Web of Science ®Google Scholar
• Srivastava G, Apovian C. Future pharmacotherapy for obesity: new anti-obesity drugs on the horizon. Curr Obes Rep. 2018 Jun;7(2):147–161.
   PubMed Web of Science ®Google Scholar
• EMA. Zonegran EPAR product information. [cited 2019 Jan 2]. Available from: https://www.ema.europa.eu/documents/product-information/zonegran-epar-product-information_en.pdf
   Google Scholar
• FDA label database: zonegran. [cited 2019 Jan 2]. Available from: http://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setId=d12de43e-3ac3-4335-bc85-70d7366a91eb.
   Google Scholar
• Sills G, Brodie M. Pharmacokinetics and drug interactions with zonisamide. Epilepsia. 2007 Mar;48(3):435–441.
   PubMed Web of Science ®Google Scholar
• Miura H. Zonisamide monotherapy with once-daily dosing in children with cryptogenic localization-related epilepsies: clinical effects and pharmacokinetic studies. Seizure. 2004 Dec;13(Suppl 1):S17–S23. discussion S24-5.
   PubMed Web of Science ®Google Scholar
• Wallander KM, Ohman I, Dahlin M. Zonisamide: pharmacokinetics, efficacy, and adverse events in children with epilepsy. Neuropediatrics. 2014 Dec;45(6):362–370.
   PubMed Web of Science ®Google Scholar
• Eun SH, Kim HD, Eun BL, et al. Comparative trial of low- and high-dose zonisamide as monotherapy for childhood epilepsy. Seizure. 2011 Sep;20(7):558–563.
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs–best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008 Jul;49(7):1239–1276.
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Duncan R, Vespignani H, et al. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia. 2005 Jan;46(1):31–41.
   Web of Science ®Google Scholar
• Faught E, Ayala R, Montouris GG, et al. Zonisamide 922 Trial G. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology. 2001 Nov 27;57(10):1774–1779.
   PubMed Web of Science ®Google Scholar
• Sackellares JC, Ramsay RE, Wilder BJ, et al. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia. 2004 Jun;45(6):610–617.
   PubMed Web of Science ®Google Scholar
• Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res. 1993 May;15(1):67–73.
   PubMed Web of Science ®Google Scholar
• Baulac M, Brodie MJ, Patten A, et al. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2012 Jul;11(7):579–588.
   PubMed Web of Science ®Google Scholar
• Guerrini R, Rosati A, Segieth J, et al. A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy. Epilepsia. 2013 Aug;54(8):1473–1480.
   PubMed Web of Science ®Google Scholar
• Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013 Mar;54(3):551–563.
   PubMed Web of Science ®Google Scholar
• Brigo F, Lattanzi S, Igwe SC, et al. Zonisamide add-on therapy for focal epilepsy. Cochrane Database Syst Rev. 2018 Oct 18;10:CD001416.
   PubMed Web of Science ®Google Scholar
• Baulac M, Patten A, Giorgi L. Long-term safety and efficacy of zonisamide versus carbamazepine monotherapy for treatment of partial seizures in adults with newly diagnosed epilepsy: results of a phase III, randomized, double-blind study. Epilepsia. 2014 Oct;55(10):1534–1543.
   PubMed Web of Science ®Google Scholar
• Wroe SJ, Yeates AB, Marshall A. Long-term safety and efficacy of zonisamide in patients with refractory partial-onset epilepsy. Acta Neurol Scand. 2008 Aug;118(2):87–93.
   PubMed Web of Science ®Google Scholar
• Guerrini R, Rosati A, Bradshaw K, et al. Adjunctive zonisamide therapy in the long-term treatment of children with partial epilepsy: results of an open-label extension study of a phase III, randomized, double-blind, placebo-controlled trial. Epilepsia. 2014 Apr;55(4):568–578.
   PubMed Web of Science ®Google Scholar
• Shinnar S, Pellock JM, Conry JA. Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. Eur J Paediatr Neurol. 2009 Jan;13(1):3–9.
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Zaccara G, Giovannelli F, et al. Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta-analysis. Acta Neurol Scand. 2019 Jan;139(1):33–41.
   PubMed Web of Science ®Google Scholar
• Zaccara G, Specchio LM. Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249–259.
   PubMed Web of Science ®Google Scholar
• Toledo M, Beale R, Evans JS, et al. Long-term retention rates for antiepileptic drugs: A review of long-term extension studies and comparison with brivaracetam. Epilepsy Res. 2017;138:53–61.
   PubMed Web of Science ®Google Scholar
• Nakken KO, Lindstrom P, Andersen H. Retention rate of zonisamide in intractable epilepsy. Acta Neurol Scand. 2015 May;131(5):268–274.
   PubMed Web of Science ®Google Scholar
• Chung S, Wang N, Hank N. Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure. 2007 Jun;16(4):296–304.
   PubMed Web of Science ®Google Scholar
• Kim DW, Choi K, Moon HS, et al. Long-term retention rate of zonisamide in patients with epilepsy: an observational study. Clin Neuropharmacol. 2014 Sep-Oct;37(5):133–135.
   PubMed Web of Science ®Google Scholar
• Velizarova R, Crespel A, Genton P, et al. Zonisamide for refractory juvenile absence epilepsy. Epilepsy Res. 2014 Sep;108(7):1263–1266.
   PubMed Web of Science ®Google Scholar
• Ohtahara S. Zonisamide in the management of epilepsy–japanese experience. Epilepsy Res. 2006 Feb;68(Suppl 2):S25–S33.
   PubMed Web of Science ®Google Scholar
• Farrokh S, Bon J, Erdman M, et al. Use of newer anticonvulsants for the treatment of status epilepticus. Pharmacotherapy. 2019 Feb 5. doi: 10.1002/phar.2229. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Park SP, Hwang YH, Lee HW, et al. Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients. Epilepsy Behav. 2008 Jan;12(1):102–108.
   PubMed Web of Science ®Google Scholar
• Arif H, Buchsbaum R, Weintraub D, et al. Patient-reported cognitive side effects of antiepileptic drugs: predictors and comparison of all commonly used antiepileptic drugs. Epilepsy Behav. 2009 Jan;14(1):202–209.
   PubMed Web of Science ®Google Scholar
• Mertens LJ, Witt JA, Helmstaedter C. Affective and behavioral dysfunction under antiepileptic drugs in epilepsy: development of a new drug-sensitive screening tool. Epilepsy Behav. 2018 Jun;83:175–180.
   PubMed Web of Science ®Google Scholar
• White JR, Walczak TS, Marino SE, et al. Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study. Neurology. 2010 Aug 10;75(6):513–518.
   PubMed Web of Science ®Google Scholar
• Witt JA, Helmstaedter C. Monitoring the cognitive effects of antiepileptic pharmacotherapy–approaching the individual patient. Epilepsy Behav. 2013 Mar;26(3):450–456.
   PubMed Web of Science ®Google Scholar
• Witt JA, Helmstaedter C. How can we overcome neuropsychological adverse effects of antiepileptic drugs? Expert Opin Pharmacother. 2017 Apr;18(6):551–554.
   PubMed Web of Science ®Google Scholar
• Witt JA, Elger CE, Helmstaedter C. Adverse cognitive effects of antiepileptic pharmacotherapy: each additional drug matters. Eur Neuropsychopharmacol. 2015 Nov;25(11):1954–1959.
   PubMed Web of Science ®Google Scholar
• Chen B, Detyniecki K, Hirsch LJ, et al. Cross-sensitivity of patient-perceived adverse cognitive effects with antiepileptic drug use. Epilepsy Behav. 2015;46:151–157.
   PubMed Web of Science ®Google Scholar
• Vari MS, Striano P. A review of safety and efficacy of zonisamide for treatment of pediatric partial epilepsy. Pediatric Health Med Ther. 2014;2014:155–160.
   Google Scholar
• WHO. WHO drug information Vol. 17, No. 1, 2003. [cited 2018 Dec 21]. Available from: http://apps.who.int/medicinedocs/en/d/Js4953e/4.6.html#Js4953e.4.6
   Google Scholar
• Domecq JP, Prutsky G, Leppin A, et al. Clinical review: drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015 Feb;100(2):363–370.
   PubMed Web of Science ®Google Scholar
• Verrotti A, Loiacono G, Di Sabatino F, et al. The adverse event profile of zonisamide: a meta-analysis. Acta Neurol Scand. 2013 Nov;128(5):297–304.
   PubMed Web of Science ®Google Scholar
• Lagae L, Meshram C, Giorgi L, et al. Effects of adjunctive zonisamide treatment on weight and body mass index in children with partial epilepsy. Acta Neurol Scand. 2015 May;131(5):341–346.
   PubMed Web of Science ®Google Scholar
• Gadde KM, Kopping MF, Wagner HR 2nd, et al. Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. Arch Intern Med. 2012 Nov 12;172(20):1557–1564.
   PubMedGoogle Scholar
• Jion YI, Raff A, Grosberg BM, et al. The risk and management of kidney stones from the use of topiramate and zonisamide in migraine and idiopathic intracranial hypertension. Headache. 2015 Jan;55(1):161–166.
   PubMed Web of Science ®Google Scholar
• Wroe S. Zonisamide and renal calculi in patients with epilepsy: how big an issue? Curr Med Res Opin. 2007 Aug;23(8):1765–1773.
   PubMed Web of Science ®Google Scholar
• Hernandez-Diaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012 May 22;78(21):1692–1699.
   PubMed Web of Science ®Google Scholar
• Borrelli EP, Lee EY, Descoteaux AM, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: an analysis of the us food and drug administration adverse event reporting system. Epilepsia. 2018 Dec;59(12):2318–2324.
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA, Yang LP. Topiramate: a review of its use in the treatment of epilepsy. Drugs. 2007;67(15):2231–2256.
   PubMed Web of Science ®Google Scholar
• Campos MS, Ayres LR, Morelo MR, et al. Efficacy and tolerability of antiepileptic drugs in patients with focal epilepsy: systematic review and network meta-analyses. Pharmacotherapy. 2016 Dec;36(12):1255–1271.
   PubMed Web of Science ®Google Scholar
• Dainippon Sumitomo Pharma. Notice of launching of a new Parkinson’s disease drug “TRERIEF®. 2009. [cited 2018 Dec 21]. Available from: https://www.ds-pharma.com/ir/news/pdf/ene20090313.pdf
   Google Scholar
• Dainippon Sumitomo Pharma. Sumitomo Dainippon Pharma Obtains Approval in Japan for TRERIEF®, a therapeutic agent for Parkinson’s disease, for an additional indication of parkinsonism in dementia with lewy bodies. 2018. [cited 2018 Dec 21]. Available from: https://www.ds-pharma.com/ir/news/pdf/ene20180702.pdf
   Google Scholar